A Pilot Study on Intermittent and Repeated Dosing of Ibrutinib in the Treatment of Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Acronyms IbruOnOff
- 01 Mar 2021 New trial record